BIO
Theodore holds a Bachelor of Science in Economics from University College London. He currently serves as Deputy Chief Executive Officer and a member of the Board at Fortune Pharmacal, where he leads the company’s sustainability strategy. Fortune has advanced its carbon accounting across Scopes 1, 2, and 3, and recently achieved B Corp certification, reflecting its commitment to responsible and sustainable business practices.
ABOUT THE COMPANY
Founded in 1954, Fortune Pharmacal has grown alongside the people of Hong Kong, providing trusted over-the-counter (OTC) medicines that support everyday health and resilience. For more than half a century, we have invested in our own research, development, and manufacturing capabilities locally in Hong Kong so that quality, safety, and accessibility remain firmly in our own hands. Our commitment to “always going one step further” is expressed not only in our products but also in how we manage our impact. We operate a structured environmental management system and conduct full carbon footprint accounting across our operations, giving us a clear picture of where our emissions arise and where we can make the most meaningful reductions.
As a certified B Corp, Fortune Pharmacal has formally committed to balancing profit with purpose and to being accountable for the effects of our stakeholders and reinforces our long‑standing belief that a pharmaceutical company should safeguard not only the health of patients, but also the well‑being of the communities and environments in which it operates—today and for future generations.

